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The conformationally restricted glutamate analogues, 3-alkyl-1-amino-2-
cyclopentene-1,3-dicarboxylates and N-alkylated analogues have been prepared in a 
regioselective and diastereoselective manner. From the biological studies of the 3-
alkylated analogues, compound 13b was found to be the most potent antagonist (IC50 7.7 
M) at mGluR2. Amongst the N-alkylated analogues, compound 20 was found to be a 
partial agonist (EC50 9.5 M) and as well as an antagonist (IC50 47 M) at mGluR2.  
 
*Revised Manuscript ( Including Graphical Abstract )




L-Glutamate (Glu) is the principal excitatory amino acid (EAA) neurotransmitter in 
the mammalian central nervous system (CNS) and operates through two main types of 
glutamate receptors.
1
 Those which form ligand-gated cation channels (ionotropic 
glutamate receptors, iGluRs) and those which are coupled via G-protein to intercellular 
enzyme systems which influence the production of second messengers (metabotropic 
glutamate receptors, mGluRs).
2
 Both iGluRs and mGluRs play crucial roles in the 
healthy, as well as the diseased CNS and these receptors are therefore potential targets for 
therapeutic intervention.
3
 Considerable research efforts have been focused upon the 
development of selective agonists and antagonists for iGluRs and mGluRs.
4
  
A variety of cyclic, conformationally restricted glutamate analogues have been 
prepared in laboratories around the world but only a few are highly potent and sub-type 
selective. One such compound is the conformationally restricted glutamate analogue, 
(1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid [(1S,3R)-ACPD] 1, which selectively 
activates metabotropic glutamate receptors (mGluRs) over the ionotropic type. (1S,3R)-
ACPD 1 however is not selective for the individual eight mGluR subtypes.
5
 While its 
diastereomer (1S,3S)-ACPD 2 is more potent and selective at mGluR2 (EC50 1.2 M) 








We previously reported the synthesis and biological activities of the conformational 
restricted cyclopentenyl-glutamate compound (S)-3, the dehydro-analogue of APCD. It 
was found to be an agonist at mGluR5 (EC50 18 M) and mGluR2 (EC50 45 M) 
receptors.
7
 We also reported the synthesis of the 4-phenyl substituted derivative, rac-4, 
and its aryl substituted derivatives. Compound rac-4 is a selective antagonist at mGluR2 
with modest activity with an IC50 value of 32 M.
8 
In order to further understand the SAR of the derivatives of rac-3, we aimed to 
synthesise its 3-alkylated and N-alkylated derivatives and investigate their biological 
activities.  
The synthesis of the 3-alkylated compounds can be achieved by regioselective 
deprotonation at the γ-position of the α,β–unsaturated ester moiety of protected 
derivatives of rac-3 by a strong base to generate the corresponding extended enolate 





Scheme 1. Alkylation of α,β–unsaturated ester. 
 
We report here the regioselective and diastereoselective synthesis of 3-alkylated and 
N-alkylated derivatives of (S)-3. The biological activities of these compounds as agonists 
and antagonists at mGluR2 will also be discussed.  
 
2. Results and discussion 
2.1 Synthesis of compounds 
2.1.1 Cyclopentenyl derivatives 
Racemates 9a-d and their diastereoisomers 10a-d were obtained, according to 
Scheme 2. Treating the known racemate 6
7





followed by the addition of alkylating agents gave exclusively the –alkylated products 7 
and 8 as the major and minor products, respectively. These outcomes concurred with the 
works reported by Katzenellenbogen  et al, on the –alkylation of lithium dienolates 
derived from carbonyl esters.
10
 The ratio of the isolated diastereoisomers 7 and 8 was 
determined by HPLC analysis, to be within the range of 8:2. 
 
Scheme 2. Synthesis of racemic 9 and 10. Reagents and conditions (a) KN(TMS)2, THF, -78 
o
C; RI or RBr; 
(b) 10% aq. HCl, reflux. 
 
Table 1 Isolated yields (%) of compounds 7 and 8. 
Compounds 7 (%) 8 (%) 
a (R = Me) 48 6 
b (R = CH2CHCH2) 45 6 
c (R = Bn) 77 11 




H NMR spectroscopic analysis of the two diastereomers, such as 7a and 8a 
indicated that the major diastereomer 7a exhibited a H-4 resonance ( 5.89, d, J = 4.2 Hz) 
and H-5 resonance ( 5.71, d, J = 4.2 Hz). The CH3-3 resonance at  1.49 of the major 
isomer 7a appeared more downfield than the corresponding resonance ( 1.32) of the 
minor isomer 8a. The relative stereochemistry of 7a was determined from NOESY 
experiments that showed significant cross-peaks between the signal for H-(Ar) and H-2, 
H-2 and H-(CH3-3) and that for H-(Ar) and H-(CH3-3). These cross-peaks are 
consistent with the cis orientation of the two carboxyl groups (Fig. 2). The relative 
stereochemistries of the compounds, 8a, 8b and 7c were further unequivocally 
determined by X-ray structure analysis (Figs. 3-5).
11
  Suitable crystals for X-ray analysis 
of compounds 8a, 8b and 7d were grown from a mixture of ethyl acetate and hexane. 
 
 





Figure 3. ORTEP diagram of the structure of compound 8a. Ellipsoids have been drawn 
at the 20% probability level. 
 
 
Figure 4. ORTEP diagram of the structure of compound 8b. Ellipsoids have been drawn 





Figure 5. ORTEP diagram of the structure of compound 7c. Ellipsoids have been drawn 
at the 30% probability level. 
 
The stereoselectivity of compound 7 over 8 can be explained, via the complexation 
of the carboxyl groups to the potassium ion. As shown in intermediate A, addition of the 
alkyl group from the upper face to intermediate A, would then give compound 7 as the 
major product as shown in Figure 6.  
 
 
Figure 6. Suggested mechanism leading to the stereochemistry of compound 7. 
 
Acid hydrolysis of 7a-d and 8a-d under similar conditions gave the hydrochloride 




Table 2 Isolated yields (%) of compounds 9 and 10. 
Compounds 9 10 
a (R = Me) 86 80 
b (R = CH2CHCH2) 100 100 
c (R = Bn) 94 98 
d [R = (CH2)3Ph] 63 76 
 
2.1.2 Cyclopentyl derivatives 
The racemic cyclopentyl derivatives, 13 and 14, were synthesised, according to 
Scheme 3. Removal of diphenyl methylene group from 7 and 8 by a mild acid hydrolysis 
followed by hydrogenation proceeded smoothly to give 11 and 12, respectively, in good 
yields.  
Acid hydrolysis of 11a-c and 12c gave the hydrochloride salts of 13a-c and 14c, 
respectively (Table 3).  
 
 
Scheme 3.  Synthesis of racemic 13 and 14. Reagents and conditions (a) (i) 1 M HCl, ether, RT, 16 h, (ii) 
Pd/C, H2, MeOH, RT, (b) 10% aq. HCl, reflux. 
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Table 3 Isolated yields (%) of compounds 11, 12, 13 and 14. 
Compounds 11 12 13 14 





b (R = Pr) 94 93 99 na
a
 
c (R = Bn) 66 70 86 85 
a
na : not attempted 
2.1.2  N, N-Dimethylated analogues 
The synthesis of N-alkylated compound 16 is shown in Scheme 4. Treatment of 
racemic 15
8
 with formaldehyde, NaBH3CN, acetic acid in dry methanol afforded 16 in 
70% yield which was hydrolysed in aqueous 10% HCl to give the hydrochloride salt of 
17 in 98% yield.  
With compound 16 in hand, it was further reduced using Mg turnings in dry 
methanol to give a mixture of diastereomers, cis 18 and the trans 19, as the major and 
minor diastereoisomers respectively, in the ratio of 4:1, respectively. The major 
diastereoisomer 18 was hydrolysed to afford 20 in a quantitative yield. 
 
 
Scheme 4. Synthesis of racemic 17 and 20.  Reagents and conditions (a) HCHO, NaBH3CN, acetic acid, 





H NMR spectroscopic analysis of the two diastereomers 18 and 19 indicated that the 
major diastereomer 18 exhibited a H-3 resonance at  2.92 (dq) more downfield than the 
corresponding resonance ( 2.84, dq) of the minor isomer 19. 
The relative stereochemistry of compound 18 was determined by NOESY 
experiments that showed significant cross peaks between the signal for H-3 and H-2 
and that for H-2 and H-(CH3). These confirmed the cis orientation of the two carboxyl 
groups (Fig. 7). 
 
 
Figure 7.  NOESY correlations for compound 18.  
 
Reduction of ,–unsaturated esters and other electron deficient alkenes using 
magnesium metal in dry methanol has been described by us and others to be a selective 
and efficient method to provide the desired cis 18 as the major product.
8, 12-14
 The cis 
orientation of the two carboxylic groups in 18 is considered to be significant structural 
features for activities.
6
 The selectivity observed in the magnesium-methanol reduction of 
compound 16 might be due to the formation of the Mg(II) complex B, as shown in Figure 





Figure 8. Suggested mechanism leading to the stereochemistry of compound 18. 
 
2.1.3 N-alkylated analogues 
The racemic N-alkylated compounds 22a-e were obtained according to Scheme 5, 
the imine intermediates 21a-e were obtained by treating the known 15
8
 with various 
aldehydes in dry THF in the presence of powdered molecular sieves, then followed by the 
reduction in the presence of NaBH3CN and acetic acid, in methanol to afford 21a-e in 
acceptable yields. Acid hydrolysis of 21a-e provided the hydrochloride salts of 




Scheme 5. Synthesis of racemic 22. Reagents and conditions (a) (i) RCHO, THF, powdered molecular 
sieves (5 Å), RT, (ii) NaBH3CN, acetic acid, MeOH; (b) 10% aq. HCl, reflux.  
 
Table 4 Isolated yields (%) of compounds 21 and 22. 
Compounds 21 22 
a (R = Ph) 80 98 
b (R = 2-pyridinyl) 80 100 
c (R = 3-pyridinyl) 58 98 
d [R = 3-(OH)C6H4] 81 92 




2.2 Biological studies: Signal transduction at cloned metabotropic glutamate 
receptors 
Signal transduction experiments were performed with CHO cells heterologously 
expressing human mGlu2 receptors. Signalling at the mGlu2 receptor was measured by 
mean of a [
35
S]GTPS binding assay on membranes from these cells.
5
 The results for the 
agonist and antagonist activities are summarised in Table 5. 
 
Table 5 Agonist and antagonist activities of synthesised compounds.  
Compounds 
mGlu2-ago-AC,  
EC50  SD in 
M (Emax%) 
mGlu2-ago-GTP,  
EC50  SD in M 
(Emax%) 
mGlu2-antag-GTP, 
IC50  SD in M 
(Emax%) 





 45  10 (38%)
a
 60 (39%) 












 200 (67%) 
rac-17 3(51%) >100 >100 
rac-20 nd
b
 9.7  0.5 (34%) 47 (66%) 
rac-22b nd
b
 >100 75  11 (100%) 
rac-22c nd
b
 >100 >100 
a
Values from reference 7. 
b
nd: not determined. 
c
No full dose response. 
 
Three compounds, namely 9a, 17 and 20 were found to be mGlu2 agonists. 
Compound 17 was shown to exhibit mGluR2 agonism in the adenyl cyclase assay, with 
the potency of 3 M with an Emax of 51% of the maximal glutamate response. However, 
the agonist activity of 17 was not confirmed in the [
35
S]GTPS binding experiment, 
where this compound was expected to activate radioligand binding.  Compound 17 was 
also shown to have inhibitory activity at the AMPA receptor in a glycine binding assay 
with an IC50 value of 6.8 M (data is not shown). 
13 
 
The most active agonist in this series was 20 with a potency of EC50 9.5 M and an 
Emax of 34% of the maximal glutamate response. This compound also had inherent partial 
antagonist activity with an IC50 of 47 M. The concentration-response curves illustrated 









Full antagonistic activities were found amongst the saturated (13b and 20), as well as 
unsaturated (22b) ring structures. The most potent antagonist was 13b with an IC50 of 7.7 
M. The concentration-response curve revealed that 13b was an antagonist with full 
inhibition of glutamate signalling in the [
35
S]GTPS binding assay, obtained from two 




Figure 10. Antagonist activity of 13b and antagonist activity of 22b at mGluR2. 
 
Only one compound in this series, namely 22c, was found to be an inhibitor at the 
glycine site of the NMDA receptor with an IC50 of 1.9 M (data is not shown), as 
measured in rat cortical membranes by radio-ligand binding. 
The other synthesised compounds in this series were found to be inactive on the 
tested receptors.  
By comparing the activities of the saturated and unsaturated compound pairs, such as 
9b and 13b, it would appear that reduction of the double bond results in an improvement 
in the antagonist potency. Compound 9b is not active in tested mGluR receptors, while 
13b is a selective antagonist at mGluR2. Within the structures of the saturated active 
analogues, they were found to have the carboxylic groups in the cis configuration. This 
was observed in the compound pair 17 and 20. The unsaturated analogue 17 showed no 
activity in the mGluR2 [
35
S]GTPS binding assay. Compound 20 was the most active 
agonist as well as a partial antagonist. This structural feature was also found important in 
rac-4 and its active analogues and the well-known (1S,3S)-ACPA
6
. In summary, our 
results reveal that the ring flexibility and the cis orientation of the two carboxylic groups 





In conclusion, through this undertaking we have successfully prepared 3–alkylated 
and N-alkylated derivatives of rac-3 in a regioselective and diastereoselective manner. In 
this series of compounds, we have discovered a number of novel mGluR2 agonists and 
antagonists with potency in the low M range. Although, the conclusive structural 
activity relationship remains complex, we have however gained a clearer understanding 




Solvents and reagents were purchased from commercial sources and used without further 
purification unless otherwise stated. Unless specified, all NMR spectra were recorded at 
300 MHz (
1
H NMR) or 75 MHz (
13
C NMR) in CDCl3 solution. 
13
C NMR assignments 
were based on DEPT experiments. Preparative HPLC was performed using a Waters 
Delta prep 4000 HPLC, on a normal phase Pre Nova-Pak HR Silica 6 m 60 (25 × 10 
mm) column. All separations were carried out by isocratic elution, using eluents A and B 
(A, in petroleum spirit; B, ethyl acetate) in the ratio 98:2. The flow rate was at 20 
mL/min. Compounds were detected using a Waters 486 tunable UV absorbance detector.  
 
4.2 Biological Testing 
[
35
S]GTPS (specific activity 37 MBq/ml) was obtained from Amersham (Little Chalfort, 
UK). Dulbecco’s modified Eagle medium (DMEM) and dialyzed fetal calf serum were 
from Life technologies (Gaithersburg, MD). Scintillation fluid Ultimaflo AF as well as 
the Unifilter-96 GF/B plates were from Packard (Meriden, CT). Guanosine-5’-
diphosphate dilithium salt (GDP) was from Boehringer Manheim (Basel, Switzerland), 
Fluo 3-AM was from Molecular Probes (Leiden, The Netherlands). Probenecid was from 
Sigma (St. Louis, MO). Black 96-well plates were from Costar (Merck, Overijse 
Belgium). 
 




To a solution of compound 6 (0.552 g, 1.46 mmol) in dry THF (12 mL) at -78 
o
C was 
added a solution of KN(TMS)2 (2.5 equiv., 7.3 mL, 3.66 mmol, 0.5 M in THF). After 
stirring for 1 h, a solution of methyl iodide (10 equiv., 0.9 mL, 14.6 mmol) in dry THF (2 
mL) was added drop wise to the mixture and the stirring continued for another 1 h. The 
reaction mixture was allowed to warm to RT over 1 h then was diluted with a saturated 
aqueous solution of NaCl, and then extracted with ether. The combined organic extracts 
were dried over MgSO4 and the solvent was removed to give a dark yellow residue which 
was purified by column chromatography (ethyl acetate/petroleum spirit, 1:9) to give a 
mixture of diastereomers (54%) in the ratio of 8:1 as determined by 
1
H NMR 
spectroscopic analysis. The two diastereomers were separated by HPLC (ethyl 
acetate/petroleum spirit, 5:95).  
Major isomer 7a, a yellow solid (0.274 g, 48%). Rf (5% ethyl acetate/ petroleum spirit) 
0.28. 
1
H NMR  7.60-7.12 (m, 10H), 5.89 (d, J = 4.2 Hz, 1H), 5.71 (d, J = 4.2 Hz, 1H), 
4.13-4.07 (m, 2H), 3.38 (s, 3H), 3.03 (d, J = 9.9 Hz, 1H), 2.31 (d, J = 9.9 Hz, 1H), 1.49 
(s, 3H), 1.22 (t, J = 7.2 Hz, 3H). 
13
C NMR  175.8 (C), 173.2 (C), 168.3 (C), 140.3 (C), 
137.7 (C), 133.5 (CH), 130.2 (CH), 128.7 (2CH), 128.6 (2CH), 128.4 (4CH), 127.9 
(2CH), 78.3 (C), 60.7 (CH3), 55.2 (C), 51.7 (CH2), 49.3 (CH2), 26.1 (CH3), 14.1 (CH3). 
MS (ES+) m/z 392 ([MH
+
], 80%). HRESIMS m/z 392.1817 (MH
+







Minor isomer 8a, a yellow solid (34 mg, 6%).  Rf (5% ethyl acetate/ petroleum spirit) 
0.52. 
1
H NMR  7.60-7.12 (m, 10H), 5.90 (d, J = 5.4 Hz, 1H), 5.71 (d, J = 5.4 Hz, 1H), 
4.12-4.06 (m, 2H), 3.42 (s, 3H), 2.82 (d, J = 13.8 Hz, 1H), 2.50 (d, J = 13.8 Hz, 1H), 
1.32 (s, 3H), 1.26 (t, J = 6.9 Hz , 3H). 
13
C NMR  176.1 (C), 173.6 (C), 168.2 (C), 140.3 
(C), 137.6 (C), 133.9 (CH), 130.2 (CH), 128.8 (2CH), 128.7 (2CH), 128.4 (4CH), 127.9 
(2CH), 78.5 (C), 60.8 (CH3), 55.3 (C), 51.9 (CH2), 47.9 (CH2), 25.4 (CH3), 14.2 (CH3). 
MS (ES+) m/z 392 ([M+H], 85%). HRESIMS m/z 392.1815 (MH
+







 (1R*,3R*)-1-Ethyl 3-methyl 1-allyl-3-(diphenylmethyleneamino)cyclopent-4-ene-
1,3-dicarboxylate (7b) 
Major isomer 7b (0.274 g, 45%) yellow solid. Rf (5% ethyl acetate/ petroleum spirit) 
0.36. 
1
H NMR  7.57-7.12 (m, 10H), 5.94 (d, J = 5.4 Hz, 1H), 5.76 (d, J = 5.4 Hz, 1H), 
5.82-5.68 (m, 1H), 5.76 (d, J = 5.4 Hz, 1H), 5.14-5.10 (m, 1H), 5.09-5.07 (m, 1H) 4.15-
4.05 (m , 2H), 3.39 (s, 3H), 2.96 (d, J = 13.7 Hz, 1H), 2.67-2.52 (m, 2H), 2.40 (d, J = 
13.7 Hz, 1H), 1.22 (t, J = 6.9 Hz, 3H). 
13
C NMR  174.4 (C), 173.1 (C), 168.2 (C), 140.2 
(C), 137.4 (C), 136.0 (CH), 134.2 (CH), 133.7 (CH), 132.3 (C), 130.2 (CH), 129.9 (CH), 
128.7 (CH), 128.5 (CH), 128.3 (2CH), 128.2 (CH), 127.9 (2CH), 118.1 (CH2), 78.1 (C), 





], 100.0%). HRESIMS m/z 418.2014 [MH]
+






dicarboxylate (8b)  
Minor isomer 8b, a yellow solid (36.6 mg, 6%). Rf (5% ethyl acetate/ petroleum spirit) 
0.54. 
1
H NMR  7.57-7.12 (m, 10H), 5.93 (d, J = 5.6 Hz, 1H), 5.77 (d, J = 5.6 Hz, 1H), 
5.73-5.62 (m, 1H), 5.06-5.04 (br d, J = 5.6 Hz, 1H), 5.02 (br s, 1H), 4.21-4.09 (m, 2H), 
3.43 (s, 3H), 2.81 (d, J = 14.4 Hz, 1H), 2.58 (d, J = 14.4 Hz, 1H) 2.42 (d, J = 5.6 Hz, 
2H), 1.25 (t, J = 6.8 Hz, 3H). 
13
C NMR  174.7 (C), 173.5 (C), 168.1 (C), 140.2 (C), 
137.5 (C), 136.1 (CH), 134.5 (CH), 133.6 (CH),130.2 (CH), 128.8 (CH), 128.6 (CH), 
128.3 (2CH), 127.9 (3CH), 118.1 (CH2), 78.1 (C), 60.8 (CH2), 59.4 (C), 51.9 (CH3), 45.8 
(CH2), 42.2 (CH2), 14.3 (CH3). MS (ES
+
) m/z 418.19 ([MH
+
], 100.0%). HRESIMS m/z 
418.2013 (MH
+




4.3.2 General procedure for alkylation of 6 
To a solution of compound 6 (0.552 g, 1.46 mmol) in dry THF (12 mL) at -78 
o
C was 
added a solution of KN(TMS)2 (2.5 equiv., 7.3 mL, 3.66 mmol, 0.5 M in THF ). After 
18 
 
stirring for 1 h, a solution of alkyl bromide (2.5 equiv., 3.7 mmol) in dry THF (2 mL) was 
added drop wise to the mixture and the stirring continued for another 1 h. The reaction 
mixture was allowed to warm to RT over 1 h then was diluted with a saturated aqueous 
solution of NaCl, and then extracted with ether. The combined organic extracts were 
dried over MgSO4 and the solvent was removed to give a dark yellow residue which was 
purified by column chromatography (ethyl acetate/petroleum spirit, 1:9) to give a mixture 
of diastereomers. The two diastereomers were separated by HPLC (ethyl 




Major isomer 7c, a yellow solid (0.525 g, 77%). Rf (5% ethyl acetate/ petroleum spirit) 
0.35. 
1
H NMR  7.62-7.59 (m, 2H), 7.43-7.12 (m, 13H), 5.93 (d, J = 5.7 Hz, 1H), 5.75 
(d, J = 5.7 Hz, 1H), 4.02 (q, J = 7.2 Hz. 2H), 3.38 (s, 3H), 3.28 (d, J = 13.2 Hz, 1H), 3.13 
(d, J = 13.2 Hz, 1H), 2.91 (d, J = 13.5 Hz, 1H), 2.56 (d, J = 13.5 Hz, 1H), 1.14 (t, J = 7.2 
Hz, 3H). 
13
C NMR  174.2 (C), 173.8 (C), 168.2 (C), 144.1 (C), 140.0 (C), 137.4 (C), 
136.2 (CH), 133.8 (CH), 130.2 (2CH), 129.7 (2CH), 128.7 (4CH), 128.5 (2CH), 128.2 
(2CH), 128.0 (CH), 127.9 (CH), 126.5 (CH), 77.9 (C), 60.7 (CH2), 60.5 (C), 51.7 (CH3), 
47.4 (CH2), 45.6 (CH2), 13.9 (CH3). MS (ES+) m/z 468.0 ([M+H], 100.0%), Anal. calcd 
for C30H29NO4: C, 77.06; H, 6.25; N, 3.00. Found: C, 77.31; H, 6.38; N, 2.75. 
 
(1R*,3S*)-1-Ethyl 3-methyl 1-benzyl-3-(diphenylmethyleneamino)cyclopent-4-ene-
1,3-dicarboxylate (8c)  
Minor isomer 8c, a yellow solid (75.0 mg, 11%). Rf (5% ethyl acetate/ petroleum spirit) 
0.65. 
1
H NMR  7.82-7.80 (m, 2H), 7.60-7.08 (m, 13H), 5.92 (d, J = 5.4 Hz, 1H), 5.80 
(d, J = 5.4 Hz, 1H), 4.10-4.02 (m, 2H), 3.45 (s, 3H), 3.06 (d, J = 13.2 Hz, 1H), 2.96 (d, J 
= 13.2 Hz, 1H), 2.74 (s, 2H), 1.14 (t, J = 7.2 Hz, 3H). 
13
C NMR  174.1 (C), 173.6 (C), 
168.3 (C), 144.3 (C), 139.8 (C), 137.3 (C), 136.2 (CH), 133.6 (CH), 130.1 (2CH), 129.4 
(2CH), 129.0 (4CH), 128.8 (2CH), 128.3 (2CH), 128.1 (CH), 127.5 (CH), 126.1 (CH), 
77.6 (C), 61.0 (C), 60.3 (CH2), 52.0 (CH3), 48.3 (CH2), 45.8 (CH2), 14.0 (CH3). MS 
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(ES+) m/z 468.0 ([MH
+
], 100.0%). Anal. calcd for C30H29NO4: C, 77.06; H, 6.25; N, 




Major isomer 7d, a yellow oil (0.260 g, 36%). Rf (5% ethyl acetate/ petroleum spirit) 
0.36. 
1
H NMR  7.58-7.09 (m, 15H), 5.93 (d, J = 5.4 Hz, 1H), 5.71 (d, J = 5.4 Hz, 1H), 
4.11-4.05 (m , 2H), 3.39 (s, 3H), 3.01 (d, J = 13.6 Hz, 1H), 2.68-2.56 (m, 2H), 2.33 (d, J 
= 13.6 Hz, 1H), 1.94-1.79 (m, 2H), 1.68-1.60 (m, 2H), 1.20 (t, J = 6.8 Hz , 3H). 
13
C 
NMR  174.8 (C), 173.0 (C), 168.1 (C), 141.7 (C), 140.0 (C), 137.2 (C), 136.1 (CH), 
133.7 (CH), 130.1 (CH), 128.6 (CH), 128.4 (2CH), 128.2 (2CH), 128.1 (4CH), 127.8 
(2CH), 127.7 (2CH), 125.6 (CH), 77.8 (C), 60.5 (CH2), 59.2 (C), 51.6 (CH3), 47.4 (CH2), 
39.1 (CH2), 35.9 (CH2), 27.0 (CH2), 13.9 (CH3). MS (ES+) m/z 496.0 ([MH
+
], 100.0%). 
HRESIMS m/z 496.2488 (MH
+






Minor isomer 8d, a yellow oil (11.6 mg, 1.6%). Rf (5% ethyl acetate/ petroleum spirit) 
0.54. 
1
H NMR  7.56-7.11 (m, 15 H), 5.93 (d, J = 5.4 Hz, 1H), 5.73 (d, J = 5.4 Hz, 1H), 
4.18-4.07 (m, 2H), 3.39 (s, 3H), 2.83 (d, J = 13.5 Hz, 1H), 2.57-2.54 (m, 2H), 2.52 (d, J 
= 13.5 Hz, 1H), 1.76-1.67 (m, 2H), 1.61-1.51 (m, 2H), 1.22 (t, J = 6.9 Hz,  3H). 
13
C 
NMR  175.2 (C), 173.5 (C), 168.0 (C), 142.0 (C), 140.2 (C), 137.5 (C), 136.4 (CH), 
134.0 (CH), 130.2 (CH), 128.7 (CH), 128.6 (2CH), 128.3 (4CH), 128.2 (2CH), 127.8 
(4CH), 125.7 (CH), 78.1 (C), 60.6 (CH2), 59.4 (C), 51.8 (CH3), 46.6 (CH2), 38.7 (CH2), 
35.9 (CH2), 27.2 (CH2), 14.2 (CH3). MS (ES+) m/z 496.0 ([MH
+
], 100.0%). HRESIMS 
m/z 496.2488 (MH
+
), calcd for C32H34NO4 (MH
+
) 496.2493.  
 
4.3.3 General hydrolysis procedure for 7 and 8 
Compound 7a (0.270 g, 0.70 mmol) in 10% aq. HCl (3 mL) was heated at 80 
o
C for 16 h. 
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After cooling, the reaction mixture was diluted with water (2 mL) and washed with ether 
(5 mL). The water was removed under reduced pressure to give the HCl salt of 9a as a 
white solid (0.133 g, 86%). 
 
(1R*,3R*)-1-Amino-3-methylcyclopent-4-ene-1,3-dicarboxylic acid (9a) 
A white solid (0.133 g, 86%). 
1
H NMR (D2O)  6.14 (d, J = 5.4 Hz, 1H), 5.65 (d, J = 5.4 
Hz, 1H), 3.01 (d, J = 14.7 Hz, 1H), 1.86 (d, J = 14.7 Hz, 1H), 1.30 (s, 3H). 
13
C NMR 
(D2O)  176.2 (C), 169.9 (C), 141.1 (CH), 124.0 (CH), 66.3 (C), 53.8 (C), 40.9 (CH2), 
22.0 (CH3). MS (ES+) m/z 186.0 ([MH
+







(1R*,3S*)-1-Amino-3-methylcyclopent-4-ene-1,3-dicarboxylic acid (10a) 
A white solid (0.124 g, 80%). 
1
H NMR (D2O)  6.18 (d, J = 5.4 Hz, 1H), 5.72 (d, J = 5.4 
Hz, 1H), 2.59 (d, J = 15.3 Hz, 1H), 2.35 (d, J = 15.3 Hz, 1H), 1.32 (s, 3H). 
13
C NMR 
(D2O)  176.2 (C), 169.9 (C), 141.1 (CH), 124.0 (CH), 66.5 (C), 53.8 (C), 40.9 (CH2), 
22.0 (CH3). MS (ES+) m/z 186 ([MH
+
], 60%). HRESIMS m/z 186.0763 (MH
+





(1R*,3R*)-1-Allyl-3-aminocyclopent-4-ene-1,3-dicarboxylic acid (9b) 
A pale yellow solid (0.170 g, 100%). 
1
H NMR (D2O)  6.31 (d, J = 5.7 Hz, 1H), 5.80 (d, 
J = 5.7 Hz, 1H), 5.78-5.64 (m, 1H), 5.12 (br d, J = 4.8 Hz, 1H), 5.08 (br s, 1H), 3.03 (d, J 
= 15.0 Hz, 1H), 2.49 (br d, J = 4.8 Hz, 2H), 2.04 (d, J = 15.0 Hz, 1H). 
13
C NMR (D2O)  
174.7 (C), 169.3 (C), 139.1 (CH), 129.4 (CH), 124.5 (CH), 116.4 (CH2), 66.0 (C), 57.5 
(C), 39.6 (CH2), 38.4 (CH2). MS (ES+) m/z 212 (M+H). HRESIMS m/z 212.0919 (MH
+
), 
calcd for C10H14NO4 (MH
+
) 212.0917.  
 
(1R*,3S*)-1-Allyl-3-aminocyclopent-4-ene-1,3-dicarboxylic acid (10b) 
A pale yellow solid (22.1 mg, 100%). 
1
H NMR (D2O)  6.29 (d, J = 4.3 Hz, 1H), 5,81 (d, 
J = 4.3 Hz, 1H), 5.74-5.64 (m, 1H), 5.11-5.04 (m, 2H), 2.65-2.58 (m, 1H), 2.55 (dd, J = 
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15.0 Hz, 1H), 2.52 (d, J = 15.0 Hz, 2H), 2.47-2.41 (m, 1H). 
13
C NMR (D2O)  177.6 (C), 
172.9 (C), 143.5 (CH), 132.8 (CH), 127.9 (CH), 119.0 (CH2), 69.5 (C), 60.4 (C), 41.5 
(CH2), 40.4 (CH2). MS (ES+) m/z 212 ([MH
+
], 100%). HRESIMS m/z 212.0932 (MH
+
), 
calcd for C10H14NO4 (MH
+
) 212.0917.  
 
(1R*,3R*)-1-Amino-3-benzylcyclopent-4-ene-1,3-dicarboxylic acid (9c) 
A pale yellow solid (43.4 mg, 94%). 
1
H NMR (D2O)  7.27-7.13 (m, 5H), 6.29 (d, J = 5.7 
Hz, 1H), 5.74 (d, J = 5.7 Hz, 1H), 3.09 (d, J = 13.5 Hz, 1H), 3.01 (d, J = 14.7 Hz, 1H), 
2.98 (d, J = 13.5 Hz, 1H), 2.11 (d, J = 14.7 Hz, 1H). 
13
C NMR (D2O)  174.5 (C), 169.0 
(C), 138.8 (CH), 132.9 (C), 126.7 (2CH), 125.4 (2CH), 124.4 (CH), 124.2 (CH), 66.1 
(C), 58.7 (C), 41.2 (CH2), 38.6 (CH2). MS (ES+) m/z 262 (M+H, 30%). HRESIMS m/z 
262.1077 (MH
+
), calcd for C14H16NO4 (MH
+
) 262.1074.  
 
(1R*,3S*)-1-Amino-3-benzylcyclopent-4-ene-1,3-dicarboxylic acid (10c) 
A white solid (29.0 mg, 98%). 
1
H NMR (D2O)  7.26-7.13 (m, 5H), 6.31 (d, J = 5.7 Hz, 
1H), 5.79 (d, J = 5.4 Hz, 1H), 3.18 (d, J = 13.5 Hz, 1H), 3.03 (d, J = 13.5 Hz, 1H), 2.64 
(d, J = 15.0 Hz, 1H), 2.49 (d, J = 15.0 Hz, 1H). 
13
C NMR (D2O)  174.5 (C), 169.1 (C), 
138.9 (CH), 132.2 (C), 126.6 (2CH), 125.2 (2CH), 124.5 (CH), 124.3 (CH), 66.1 (C), 
58.6 (C), 40.9 (CH2), 38.8 (CH2). HRESIMS m/z 262.1075 (MH
+
), calcd for C14H16NO4 
(MH
+
) 262.1074.  
 
(1R*,3R*)-1-Amino-3-(3-phenylpropyl)cyclopent-4-ene-1,3-dicarboxylic acid (9d) 
A white solid (37.3 mg, 63%). 
1
H NMR (D2O)  7.25-7.15 (m, 5H), 6.25 (d, J = 5.7 Hz, 
1H), 5.72 (d, J = 5.7 Hz, 1H), 3.02 (d, J = 14.4 Hz, 1H), 2.57-2.52 (m, 2H), 1.92 (d, J = 
14.4 Hz, 1H), 1.78-1.20 (m, 4H). 
13
C NMR (D2O)  175.1 (C), 169.5 (C), 139.4 (C), 
139.1 (CH), 125.4 (4CH), 124.2 (CH), 122.9 (CH), 66.0 (C), 57.5 (C), 39.1 (CH2), 35.1 
(CH2), 31.7 (CH2), 23.2 (CH2). MS (ES+) m/z 290 ([MH
+
], 100%). HRESIMS m/z 
290.1389 (MH
+
), calcd for C16H20NO4 (MH
+




(1R*,3S*)-1-Amino-3-(3-phenylpropyl)cyclopent-4-ene-1,3-dicarboxylic acid (10d) 
A white solid (22.7 mg, 76%). 
1
H NMR (D2O)  6.95-6.80 (m, 5H), 5.94 (d, J = 5.4 Hz, 
1H), 5.45 (d, J = 5.4 Hz, 1H), 2.30 (d, J = 15.3 Hz, 1H), 2.21 (t, J = 7.5 Hz, 2H), 2.12 (d, 
J = 15.3 Hz, 1H), 1.58-1.48 (m, 1H), 1.35-1.28 (m, 1H), 1.25-1.14 (m, 2H). 
13
C NMR 
(D2O)  174.2 (C), 168.7 (C), 140.7 (CH), 138.5 (C), 124.9 (4CH), 123.9 (CH), 122.4 
(CH), 66.0 (C), 57.0 (C), 37.4 (CH2), 33.1 (CH2), 31.4 (CH2), 22.7 (CH2). MS (ES
+
) m/z 
290 (M+H, 100%). HRESIMS m/z 290.1388 (MH
+





4.3.4  Representative procedure for preparation of rac-11 or rac-12 
To a stirred solution of compound 7a (0.165 g, 0.422 mmol) in diethyl ether (2 mL) at 0 
o
C, was slowly added a solution of 1 M aq. HCl (0.5 mL). The reaction mixture was 
stirred at 0 
o
C for 2 h and then at RT overnight. The reaction mixture was diluted with 
water (2 mL). The layers were separated and the aqueous layer was extracted with diethyl 
ether. Water was removed to give the crude intermediate. The crude intermediate was 
dissolved in methanol (3 mL). To the resulting solution was added Pd/C (23 mg, 0.042 
mmol). The reaction mixture was stirred at RT, under a H2 atmosphere (approx. 1 atm, 
balloon) for 24 h. The reaction mixture was filtered through a pad of celite and washed 
with methanol. Methanol was removed to give a yellow oil, which was purified by 
column chromatography (flash silica, ethyl acetate/hexane (60:40) as eluent) to give 11a 
as a yellow oil (80.3 mg, 83%). 
 
(1S*,3S*)-3-Ethyl 1-methyl 1-amino-3-methylcyclopentane-1,3-dicarboxylate (11a) 
1
H NMR (D2O)  4.15-4.06 (m, 2H), 3.78 (s, 3H), 2.95 (d, J = 15.0 Hz, 1H), 2.48 – 2.4 
(m, 1H), 2.41-2.33 (m, 1H), 2.01 (ddd, J = 4.5, 10.5, 12.0 Hz, 1H), 1.86 (d, J = 15.0 Hz, 
1H) 1.54 (ddd, J = 4.5, 10.5, 12.0 Hz, 1H), 1.39 (s, 3H), 1.19 (t, J = Hz, 3H).
13
C NMR 
(D2O)  175.0 (C), 169.5 (C), 61.1 (C), 59.1 (CH2), 52.3 (C), 50.8 (CH3), 42.2 (CH2), 
38.8 (CH2), 31.8 (CH2), 26.6 (CH3), 10.62 (CH3). MS (ES
+
) m/z 230.1 (M+H, 100%). 
HRESIMS m/z 230.1389 (MH
+






(1S*,3S*)-3-Ethyl 1-methyl 1-amino-3-propylcyclopentane-1,3-dicarboxylate (11b) 
A yellow oil (97.5 mg, 94%).
1
H NMR (D2O)  4.14-4.07 (m, 2H), 3.71 (s, 3H), 2.94 (d, J 
= 15.0 Hz, 1H), 2.48-2.40 (m, 1H), 2.31 (ddd, J = 4.5, 10.5, 14.4 Hz, H), 2.00 (ddd, J = 
4.5, 10.5, 14.4 Hz, 1H), 1.86 (d, J = 15.0 Hz, 1H) 1.79 – 1.66 (m, 2H), 1.54 (ddd, J = 4.5, 
10.5, 14.4 Hz, 1H), 1.18 (t, J = 6.9 Hz, 3H), 1.13 – 1.00 (m, 2H), 0.78 (t, J = 7.2 Hz, 
3H).
13
C NMR (D2O)  175.0 (C), 169.5 (C), 61.1 (C), 59.1 (CH2), 52.3 (C), 50.8 (CH3), 
42.2 (CH2), 38.8 (CH2), 31.8 (CH2), 30.3 (CH2), 15.8 (CH2), 10.6 (CH3), 10.4 (CH3). MS 
(ES
+
) m/z 258.0 (M+H, 100%). HRESIMS m/z 258.1707 (MH
+
), calcd for C13H24NO4 
(MH
+
) 258.1700.  
 
(1S*,3R*)-3-Ethyl 1-methyl 1-amino-3-benzylcyclopentane-1,3-dicarboxylate (11c) 
A yellow oil (79.0 mg, 66%). 
1
H NMR (CD3OD)  7.29-7.11 (m, 5H), 4.12-4.04 (m, 2H), 
3.78 (s, 3H), 3.13 (d, J = 13.2 Hz, 1H), 2.99 (d, J = 15.0 Hz, 1H), 2.97 (d, J = 13.2 Hz, 
1H), 2.42-2.35 (m, 2H), 2.06-2.01 (m, 3H), 1.19 (t, J = 7.2 Hz, 3H). 
13
C NMR (D2O)  
174.3 (C), 169.3 (C), 134.1 (C), 126.5 (2CH), 125.3 (2CH), 123.9 (CH), 61.5 (C), 59.9 
(CH2), 52.7 (CH3), 51.0 (C), 51.0 (CH2), 40.0 (CH2), 32.1 (CH2), 32.0 (CH2), 10.4 (CH3). 
MS (ES
+
) m/z 306 (M+H, 100%). HRESIMS m/z 306.1705 (MH
+
), calcd for C17H24NO4 
(MH
+
) 306.1700.  
 
(1S*,3R*)-3-ethyl 1-methyl 1-amino-3-propylcyclopentane-1,3-dicarboxylate (12b) 
A yellow oil (6.2 mg, 93%). 
1
H NMR (D2O)  4.12-4.09 (m, 2H), 3.71 (s, 3H), 2.94 (d, J 
= 15.0 Hz, 1H), 2.46-2.26 (m, 2H), 2.08–1.95 (m, 1H), 1.85 (d, J = 15.0 Hz, 1H), 1.78-
1.64 (m, 2H), 1.65–1.55 (m, 1H), 1.21 (t, J = 6.9 Hz, 3H), 1.0 (m, 2H), 0.80 (t, J = 7.2 
Hz, 3H). 
13
C NMR (D2O)  174.6 (C), 169.2 (C), 61.5 (C), 59.0 (CH2), 51.5 (C), 50.9 
(CH3), 40.4 (CH2), 33.0 (CH2), 32.5 (CH2), 32.2 (CH2), 19.0 (CH2), 10.7 (CH3), 10.4 
(CH3).  MS (ES
+
) m/z 258.0 (M+H, 100%). HRESIMS m/z 258.1707 (MH
+
), calcd for 
C13H24NO4 (MH
+
) 258.1700.  
 
(1S*,3S*)-3-Ethyl 1-methyl 1-amino-3-benzylcyclopentane-1,3-dicarboxylate (12c) 
A yellow oil (43.3 mg, 70%). 
1
H NMR (D2O)  7.23 (br s, 3H), 7.08 (br s, 2H), 4.09-4.07 
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(m, 2H), 3.8 (s, 3H), 3.11 (d, J = 12.6 Hz, 1H), 2.89 (d, J = 12.6 Hz, 1H), 2.51-2.26 (m, 
4H), 2.04-19.4 (m, 2H), 1.16 (t, J = 7.2 Hz, 3H). 
13
C NMR (D2O)  174.3 (C), 169.3 (C), 
134.0 (C), 126.5 (2CH), 125.3 (2CH), 123.8 (CH), 61.4 (C), 59.3 (CH2), 52.9 (CH3), 51.0 
(C), 50.9 (CH2), 39.9 (CH2), 32.1 (CH2), 32.0 (CH2), 10.3 (CH3). MS (ES
+
) m/z 306 
(M+H, 100%). HRESIMS m/z 306.1705 (MH
+
), calcd for C17H24NO4 (MH
+
) 306.1700.  
  
4.3.5 Representative procedure hydrolysis of rac-11 and rac-12 
Compound 11a (80.0 mg, 0.35 mmol) in 10% aq. HCl (2 mL) was heated at 80 
o
C for 16 
h. After cooling, the reaction mixture was diluted with water (2 mL) and washed with 
ether (5 mL). Water was removed under reduced pressure to give the HCl salt of 13a as a 
white solid (84.4 mg, 96%). 
(1S*,3S*)-1-Amino-3-methylcyclopentane-1,3-dicarboxylic acid (13a) 
1
H NMR (D2O)  2.81 (d, J = 15.0 Hz, 1H), 2.85-2.16 (m, 2H), 2.03-1.93 (m, 1H), 1.74 
(d, J = 15.0 Hz, 1H) 1.66-1.57 (m, 1H), 1.21 (s, 3H). 
13
C NMR (D2O)  180.0 (C), 173.0 
(C), 61.1 (C), 49.8 (C), 43.4 (CH2), 35.0 (CH2), 33.3 (CH2), 25.6 (CH3). MS (ES
+
) m/z 
188 (M+1, 100%). HRMSESI m/z 188.0921 (MH
+





(1S*,3S*)-1-Amino-3-propylcyclopentane-1,3-dicarboxylic acid (13b) 
A white solid (77.6 mg, 99%). 
1
H NMR (D2O)  2.91 (d, J = 15.0 Hz, 1H), 2.44-2.36 (m, 
1H), 2.29 (dd, J = 8.2, 12.0 Hz, 1H), 1.99 (ddd, J = 4.5, 8.2, 12.0 Hz, 1H), 1.83 (d, J = 
15.0 Hz, 1H) 1.78-1.64 (m, 2H), 1.54 (td, J = 4.5, 12.0 Hz, 1H), 1.24-1.03 (m, 2H), 0.78 
(t, J = 7.5 Hz, 3H). 
13
C NMR (D2O)  177.1 (C), 171.0 (C), 61.1 (C), 51.9 (C), 41.9 
(CH2), 38.7 (CH2), 31.9 (CH2), 30.3 (CH2), 15.7 (CH2), 10.5 (CH3). MS (ES
+
) m/z 216 
(M+1, 100%). HRMSESI m/z 216.1235 (MH
+




(1S*,3R*)-1-Amino-3-benzylcyclopentane-1,3-dicarboxylic acid (13c) 
A white solid (42.0 mg, 86%). 
1
H NMR (D2O)  7.26-7.11 (m, 5H), 3.05 (d, J = 13.2 Hz, 
1H), 2.90 (d, J = 15 Hz, 1H), 2.87 (d, J = 15 Hz, 1H), 2.33 – 2.20 (m, 2H), 2.03 – 1.94 
(m, 2H), 1.90-1.83 (m, 1H).
13
C NMR (D2O)  175.9 (C), 170.7 (C), 133.9 (C), 126.3 
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(2CH), 125.3 (2CH), 124.0 (CH), 61.0 (C), 53.4 (C), 41.7 (CH2), 41.3 (CH2), 31.6 (CH2), 
29.8 (CH2). MS (ES
+
) m/z 264 (M+1, 100%). HRMSESI m/z 264.1235 (MH
+





(1S*,3S*)-1-Amino-3-benzylcyclopentane-1,3-dicarboxylic acid (14c) 
A white solid (33.5 mg, 85%). 
1
H NMR (D2O)  7.25-7.12 (m, 5H), 3.14 (d, J = 13.5 Hz, 
1H), 2.84 (d, J = 13.5 Hz, 1H), 2.43- 2.35 (m, 2H), 2.30- 2.20 (m, 2H), 2.09- 1.97 (m, 
1H), 1.94-1.84 (m, 1H). 
13
C NMR (D2O)  176.8 (C), 171.0 (C), 134.1 (C), 126.4 (2CH), 
125.4 (2CH), 123.9 (CH), 61.3 (C), 52.9 (C), 39.7 (CH2), 39.6 (CH2), 32.8 (CH2), 32.0 
(CH2). MS (ES
+
) m/z 264 (M+1, 100%). HRMSESI m/z 264.1233 (MH
+





Rac-3-Ethyl 1-methyl 1-(dimethylamino)cyclopent-3-ene-1,3-dicarboxylate (16) 
To a solution of compound 15 (1.17 g, 5.48 mmol) in CH3CN (30 mL) was added a 
solution of formaldehyde (40% aq., 11.5 mL, 13.7 mmol) and NaCNBH3 (0.92 g, 14.6 
mmol). After 20 min of stirring, the pH of the reaction mixture was adjusted to pH = 4, 
by addition of acetic acid. The reaction mixture was left to stir at RT overnight. The 
mixture was diluted with a saturated aqueous solution of Na2CO3 (30 mL). The resulting 
solution was extracted twice with ethyl acetate (2 × 30 mL). The combined extracts were 
washed with a saturated solution of NaCl (30 mL) and dried over K2CO3. The solvent 
was removed under reduced pressure to give a yellow oil, which was purified by column 
chromatography (flash silica, ethyl acetate/light petroleum (1:1)) to give compound 16 
(1.14 g, 86%) as a yellow oil. 
1
H NMR  6.66 (dd, J = 1.2, 2.4, 4.5 Hz, 1H), 4.19 (q, J = 
7.2 Hz, 2H), 3.75 (s, 3H), 3.18 (dd, J = 1.2, 17.4 Hz, 2H), 3.17 (dd, J = 1.2, 17.4 Hz, 1H), 
2.76 (ddd, J = 2.4, 4.5, 17.4 Hz, 1H), 2.67 (ddd, J = 2.4, 4.5, 17.4 Hz, 1H), 2.64 (s, 6H), 
1.29 (t, J = 7.2 Hz, 3H). 
13
C NMR  173.1 (C), 164.2 (C), 140.0 (CH), 133.9 (C), 74.3 
(C), 60.2 (CH2), 51.7 (CH3), 40.2 (2CH3), 40.4 (CH2), 38.8 (CH2), 14.1 (CH3). MS (CI) 
m/z 242 (M+1, 100%). HRMSESI m/z 242.1392 (MH
+





Rac-1-(Dimethylamino)cyclopent-3-ene-1,3-dicarboxylic acid (17) 
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Compound 16 (0.100 g, 0.415 mmol) in 10% aq. HCl (2 mL) was heated at 80 
o
C for 16 
h. After cooling, the reaction mixture was diluted with water (2 mL) and washed with 
ether (5 mL). The water was removed under reduced pressure to give the HCl salt of 17 
as a white solid (95.8 mg, 96%). 
1
H NMR (D2O)  6.71-6.69 (br m, 1H), 3.27 (br d, J = 
13.8 Hz, 2H), 3.08-3.05 (br m, 1H), 3.02-3.00 (br m, 1H), 2.77 (s, 3H), 2.77 (s, 3H). 
13
C 
NMR (D2O)  168.7 (C), 163.4 (C), 137.9 (CH), 129.7 (C), 72.2 (C), 36.1 (2CH3), 36.1 
(CH2), 34.3 (CH2). MS (CI) m/z 200 (M+1, 100%). HRMSESI m/z 200.0923 (MH
+
), 




4.3.6  Reduction of compound 16 
To a solution of 16 (0.406 g, 1.62 mmol) in dry CH3OH (30 mL) under a nitrogen 
atmosphere at 0 
o
C, was added Mg turnings (0.393 g, 16.24 mmol). The reaction mixture 
was left to stir at 0 
o
C for 2 h then at RT overnight. Methanol was removed under reduced 
pressure. Water (30 mL) was added to the reaction mixture and the resulting mixture was 
extracted with ethyl acetate (3 × 40 mL). The combined organic extracted were washed 
with a saturated aqueous solution of NaCl and dried over K2CO3. The solvent was 
removed under reduced pressure to give an oil which was purified by PTLC (ethyl 
aceate/hexane (1:1)) to give compound 18 (0.107 g, 27%) and 19 (35.5 mg, 9%). 
 
(1S*,3S*)-3-Ethyl 1-methyl 1-(dimethylamino)cyclopentane-1,3-dicarboxylate (18) 
A yellow solid (0.107 g, 27%), 
1
H NMR  4.20 (q, J = 7.2 Hz, 2H), 3.70 (s, 3H), 2.92 
(ddd, J = 8.2, 8.2, 16.8 Hz, 1H), 2.47 (dd, J = 8.2, 14.0 Hz, 1H), 2.29 (s, 6H), 2.11 (dd, J 
= 8.2, 14.0 Hz, 1H), 2.09-1.98 (m, 1H), 1.94-1.71 (m, 3H), 1.29 (t, J = 7.2 Hz, 3H). 
13
C 
NMR  175.7 (C), 172.7 (C), 73.7 (C), 60.1 (CH2), 51.6 (CH3), 41.7 (CH), 40.3 (2CH3), 
37.6 (CH2), 34.4 (CH2), 27.5 (CH2), 14.1 (CH3). MS (ES+) m/z 244 (M+1, 100%). 
HRMSESI m/z 244.1547 (MH
+




(1S*,3R*)-3-Ethyl 1-methyl 1-(dimethylamino)cyclopentane-1,3-dicarboxylate (19) 
A yellow solid (35.5 mg, 9%), 
1
H NMR  4.20 (q, J = 7.2 Hz, 2H), 3.71 (s, 3H), 2.84 
(ddd, J = 7.6, 17.2, 17.2 Hz, 1H), 2.50 (dd, J = 7.6, 17.2, 1H), 2.29 (s, 6H), 2.31-2.22 (m, 
27 
 
1H), 2.06-1.78 (m, 4H), 1.29 (t, J = 7.2 Hz, 3H). 
13
C NMR  175.7 (C), 172.7 (C), 73.7 
(C), 60.1 (CH2), 51.6 (CH3), 41.7 (CH), 40.3 (2CH3), 37.6 (CH2), 34.4 (CH2), 27.5 (CH2), 
14.1 (CH3).  
 
(1S*,3S*)-1-(Dimethylamino)cyclopentane-1,3-dicarboxylic acid (20) 
To a solution of compound 18 (92.4 mg, 0.38 mmol) in THF (1.5 mL) was added 1 M aq. 
NaOH (1.5 mL) and the resulting mixture was left to stir at RT overnight. THF was 
removed and the crude product was purified by ion-exchange column chromatography, 
using Dowex
®
 1X8 (chloride form, 50-100 mesh) basic exchange resin. The crude 
product was added as a solution in 1 M aq. NH3, and after washing with demineralized 
water (120 mL), the product was eluted from the column with 1 M HCl solution to give 
the HCl salt of 20 as a white solid (87.5 mg, 97%). 
1
H NMR (D 2O)  3.00 (ddd, J = 8.4, 
8.4, 16.4 Hz, 1H), 2.74 (s, 3H), 2.71 (s, 3H), 2.45 (dd, J = 8.4, 15.2 Hz, 1H), 2.32-2.25 
(m, 2H), 2.13-1.83 (m, 3H). 
13
C NMR (D2O)  181.6 (C), 178.0 (C), 70.2 (C), 43.2 (CH), 
40.0 (CH3), 39.5 (CH3), 35.2 (CH2), 31.8 (CH2), 28.9 (CH2). MS m/z 202 (M+1, 100%). 
HRMSESI m/z 202.1077 (MH
+




4.3.7 General procedure for preparation of compound 21 
To a solution of compound 15 (0.470 g, 2.22 mmol) in dry THF (10 mL) was added the 
appropriate aldehyde (2.22 mmol) and powdered 5Å molecular sieves (2-3 g). The 
reaction mixture was left to stir at RT. Upon completion, the reaction mixture was filtered 
through a pad of celite. THF was removed under reduced pressure to give a yellow oil 
which was diluted with dry methanol (12 mL). To the resulting solution was added 
NaCNBH3 (0.280 g, 4.44 mmol). The pH of the reaction mixture was adjusted to pH = 4, 
by the addition of acetic acid. The reaction mixture was left to stir at RT for 20 h. The 
mixture was diluted with H2O (20 mL) and made basic by adding solid Na2CO3. The 
aqueous solution was extracted with CH2Cl2 and the combined extracts were dried over 
K2CO3. The solvent was removed to give a yellow oil which was purified by column 




Rac-3-Ethyl 1-methyl 1-(benzylamino)cyclopent-3-ene-1,3-dicarboxylate (21a) 
A yellow oil (0.538 g, 80%), 
1
H NMR  7.34-7.26 (m, 5H), 6.76 (dd, 2.4, 1.8 Hz, 1H), 
4.21 (q, J = 6.9 Hz, 2H), 3.78 (s, 3H), 3.66 (s, 2H), 3.19 (dd, J = 2.4, 14.7 Hz, 1H), 3.14 
(dd, J = 1.8, 16.5 Hz, 1H), 2.81 (dd, J = 2.4, 14.7 Hz, 1H), 2.70 (dd, J = 1.8, 16.5 Hz, 
1H), 2.0 (br s, 1H, NH), 1.31 (t, J = 6.9 Hz, 3H). 
13
C NMR  175.9 (C), 164.0 (C), 139.6 
(CH), 139.4 (C), 133.4 (C), 128.0 (2CH), 127.8 (2CH), 126.71 (CH), 68.8 (C), 59.9 
(CH2), 51.9 (CH3), 48.5 (CH2), 43.2 (CH2), 41.8 (CH2), 13.8 (CH3). MS (ES+) m/z 304 
(M+1, 100%). HRMSESI m/z 304.1545 (MH
+





A yellow oil (0.436 g, 80%), 
1
H NMR  8.58-8.50 (m, H), 7.71-7.59 (m, 2H), 7.30-7.18 
(m, 2H), 6.68 (br s, 1H), 4.18 (q, J = 7.2 Hz, 2H), 3.8 (s, 2H), 3.73 (s, 3H), 3.18 (ddd, J = 
2.1, 16.5, 16.5 Hz, 2H), 2.82 (dd, J = 1.5, 16.5 Hz, H), 2.72 (dd, J = 1.5, 16.5 Hz, H), 
1.28 (t, J = 7.2 Hz,  3H).
13
C NMR  175.7 (C), 164.5 (C), 159.0 (C), 149.2 (CH), 140.0 
(CH), 136.7 (CH), 133.9 (C), 122.4 (CH), 122.2 (CH), 68.9 (C), 60.4 (CH2), 52.5 (CH3), 
50.0 (CH2), 43.8 (CH2), 42.3 (CH2), 14.4 (CH3). MS (ES+) m/z 305.35 (M+1, 100%). 
HRMSESI m/z 305.1496 (MH
+






A yellow oil (0.267 g, 58%), 
1
H NMR  8.49 (d, J =1.5 Hz, 1H), 8.43 (dd, J = 1.5, 4.8 
Hz, 1H), 7.63 (dd, J = 1.5, 7.8 Hz, 1H), 7.19 (dd, J = 4.8, 7.8 Hz, 1H), 6.62 (t, 1.5 Hz, 
1H), 4.14 (q, J = 6.9 Hz, 2H), 3.72 (s, 3H), 3.61 (s, 2H), 3.10 (ddd, J = 1.5, 16.5, 16.5 Hz, 
2H), 2.72 (dd, J = 1.5, 16.5 Hz, 1H), 2.60 (dd, J = 1.5, 16.5 Hz, 1H), 2.22 (br s, 1H, NH), 
1.23 (t, J = 6.9 Hz, 3H). 
13
C NMR  175.7 (C), 164.4 (C), 149.7 (CH), 148.5 (CH), 139.8 
(CH), 136.0 (CH), 135.5 (C), 133.9 (C), 123.4 (CH), 69.0 (C), 60.4 (CH2), 52.5 (CH3), 
46.3 (CH2), 43.7 (CH2), 42.3 (CH2), 14.3 (CH3). MS (ES+) m/z 305 (M+1, 100%). 
HRMSESI m/z 305.1497 (MH
+






Rac-3-Ethyl 1-methyl 1-(3-hydroxybenzylamino)cyclopent-3-ene-1,3-dicarboxylate 
(21d) 
A yellow oil (0.163 g, 81%), 
1
H NMR  7.12 (t, J = 7.8 Hz, 1H), 6.80 (d, J = 7.8 Hz, 1H), 
6.73 (s, 1H), 6.68 (d, J = 7.8 Hz, 1H), 6.67 (t, J = 2.1 Hz, 1H), 4.17 (q, J = 6.9 Hz, 2H), 
3.75 (s, 3H), 3.52 (s, 2H), 3.13 (dd, J = 2.1, 16.9 Hz, 2H), 2.79 (d, J = 16.2 Hz, 1H), 2.69 
(dd, J = 2.1, 16.9 Hz, 1H), 1.27 (t, J = 6.9 Hz, 3H). 
13
C NMR  176.1 (C), 165.0 (C), 
156.8 (C), 140.8 (C), 140.5 (CH), 133.8 (C), 129.9 (CH), 120.2 (CH), 115.8.0 (CH), 
114.9 (CH), 69.2 (C), 60.1 (CH2), 52.8 (CH3), 49.1 (CH2), 43.7 (CH2), 42.2 (CH2), 14.4 
(CH3). MS (CI) m/z 319.36 (M, 100%). HRMSESI m/z 320.1499 (MH
+





Rac-3-Ethyl 1-methyl 1-(4-hydroxybenzylamino)cyclopent-3-ene-1,3-dicarboxylate 
(21e) 
A yellow oil (0.104 g, 69%), 
1
H NMR  7.10 (d, J = 8.4 Hz, 2H), 6.68 (t, J = 2.1 Hz, 1H), 
6.67 (d, J = 8.4 Hz, 2H),  4.17 (q, J = 7.2 Hz, 2H), 3.75 (s, 3H), 3.52 (s, 2H), 3.13 (ddd, J 
= 2.1, 16.6 Hz, 2H), 2.79 (d, J = 16.6 Hz, 1H), 2.69 (dd, J = 2.1, 16.6 Hz, 1H), 1.27 (t, J 
= 7.2 Hz, 3H). 
13
C NMR  174.1 (C), 164.9 (C), 160.3 (C), 140.5 (CH), 133.8 (C), 130.8 
(2CH), 127.6 (C), 116.0 (2CH), 75.0 (C), 68.1 (CH2), 60.9 (CH2), 53.0 (CH3), 44.6 
(CH2), 42.6 (CH2), 14.4 (CH3). MS (ES+) m/z 320 (M+1, 100%). HRMSESI m/z 
320.1498 (MH
+




4.3.8 Representative procedure for hydrolysis of compound 21 
Compound 21a (0.106 g, 0.35 mmol) in 10% aq. HCl (3 mL) was heated at 80 
o
C for 16 
h. After cooling, the reaction mixture was diluted with water (2 mL) and washed with 
ether (5 mL). The water was removed under reduced pressure to give the HCl salt of 22a 
as a white solid (102 mg, 98%). 
 
Rac-1-(Benzylamino)cyclopent-3-ene-1,3-dicarboxylic acid (22a) 
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A white solid (0.102 g, 98%), 
1
H NMR (D2O) 7.38 (s, 5H), 6.74 (br s, 1H), 4.11 (s, 2H), 
3.31 (d, J = 18.0 Hz, 2H), 3.04 (d, J = 18.0 Hz, 2H). 
13
C NMR (D2O)  169.7 (C), 163.7 
(C), 137.8 (CH), 129.5 (C), 127.4 (C), 126.6 (2CH), 126.5 (CH), 126.1 (2CH), 65.6 (C), 
44.5 (CH2), 38.5 (CH2), 36.6 (CH2). MS (CI) m/z 262 (M+1, 100%). HRMSESI m/z 
262.1078 (MH
+




Rac-1-(Pyridin-2-ylmethylamino)cyclopent-3-ene-1,3-dicarboxylic acid (22b) 
A white solid (0.202 g, 100%), 
1
H NMR (D2O)  8.65 (dd, J = 1.5, 7.8 Hz, 1H), 8.42 
(ddd, J = 1.5, 7.8, 7.8 Hz, 1H), 7.98 (d, J = 7.8 Hz, 1H), 7.88 (ddd, J = 1.5, 7.8, 7.8 Hz, 
1H), 6.63 (br s, 1H), 4.51 (s, 2H), 3.24 (br d, J = 17.4 Hz, 2H), 3.01-2.92 (m, 2H). 
13
C 
NMR (D2O)  172.3 (C), 166.6 (C), 147.9 (CH), 144.5 (C), 143.1 (CH), 140.8 (CH), 
132.62 (C), 128.8 (CH), 128.2 (CH), 69.9 (C), 43.8 (CH2), 41.8 (CH2), 40.0 (CH2). MS 
(ES+) m/z 263 (M+1, 100%). HRMSESI m/z 263.1033 (MH
+





Rac-1-(Pyridin-3-ylmethylamino)cyclopent-3-ene-1,3-dicarboxylic acid (22c) 
A white solid (0.208 g, 98%), 
1
H NMR (D2O)  8.76 (s, 1H), 8.65 (d, J = 5.7 Hz, 1H), 
8.55 (dd, J = 1.5, 8.1 Hz, 1H), 7.93 (dd, J = 5.7, 8.1 Hz, 1H), 6.58 (br s, 1H), 4.35 (s, 
2H), 3.19 (d, J = 16.8 Hz, 2H), 2.96 (d, J = 17.7 Hz, 1H), 2.91 (d, J = 17.7 Hz, 1H). 
13
C 
NMR (D2O)  172.1 (C), 166.4 (C), 148.8 (CH), 142.5 (CH), 142.3 (CH), 140.8 (CH), 
132.5 (C), 131.1 (C), 128.0 (CH), 69.4 (C), 43.8 (CH2), 41.6 (CH2), 39.8 (CH2). MS 
(ES+) m/z 263 (M+1, 100%). HRMSESI m/z 263.1033 (MH
+





Rac-1-(3-Hydroxybenzylamino)cyclopent-3-ene-1,3-dicarboxylic acid (22d) 
A yellow solid (0.113 g, 92%), 
1
H NMR (D2O)  7.20 (t, J = 7.5 Hz, 1H), 6.86 (d, J = 7.5 
Hz, 1H), 6.80 (d, J = 7.5 Hz, 1H), 6.79 (s, 1H), 6.69 (br s, 1H), 3.98 (s, 2H), 3.26 (d, J = 
17.6 Hz, 2H), 2.96 (d, J = 16.8 Hz, 2H). 
13
C NMR (D2O)  172.4 (C), 166.7 (C), 156.0 
(C), 140.9 (CH), 132.6 (C), 132.1 (C), 130.8 (CH), 121.8 (CH), 116.7 (CH), 116.6 (CH) 
68.4 (C), 47.4 (CH2), 41.6 (CH2), 39.7 (CH2). MS (CI) m/z 277.10 (M, 100%). HRMSESI 
m/z 278.1025 (MH
+






Rac-1-(4-Hydroxybenzylamino)cyclopent-3-ene-1,3-dicarboxylic acid (22e) 
A yellow solid (72.0 mg, 95%), 
1
H NMR (D2O)  7.36 (d, J = 8.1 Hz, 2H), 6.64 (d, J = 
8.1 Hz, 2H), 6.73 (br s, 1H), 4.13 (s, 2H), 3.36-3.30 (m, 2H), 3.20-3.11 (m, 2H). 
13
C 
NMR (CD3OD)  172.5 (C), 166.5 (C), 159.5 (C), 140.5 (CH), 134.6 (C), 132.8 (2CH), 
122.8 (C), 116.7 (2CH), 69.5 (C), 48.1 (CH2), 42.8 (CH2), 41.3 (CH2). MS (CI) m/z 
277.10 (M, 100%). HRMSESI m/z 278.1026 (MH
+





4.3.9  Signal transduction at mGlu2 receptors in CHO cells 
Human mGluR2 (cloned and expressed in house) were grown in DMEM/Glutamax-I to 




S]GTPS radioligand binding assay for human mGlu2 
Membrane preparation. Cells were grown to confluence. Cells were washed twice with 




, scraped off and homogenized in buffer (EDTA 
mM, Hepes 20 mM). After centrifugation (18,000 rpm, 15 min, 4 
o
C), the pellet was 
washed with 0.1 mM EDTA, 20 mM Hepes, and resuspended in the same buffer for 





S]GTPS radioligand binding. Each incubate contained 10 g of membrane protein in 
250 L of binding buffer (HEPES 20 mM, NaCl 100 mM, MgCl2 3 mM, GDP 3 M, pH 
7.4). The incubation was started by addition of an appropriate concentration of agonist 
and/or antagonist. Compounds were incubated with the membranes at 37 
o
C for 30 min. 
Subsequently, 0.1 nM [
35
S]GTPS (approximately 2  10
5
 DPM) was added in the 
presence or absence of 30 mM glutamate. The mixture was further incubated for 30 min 
at 37 
o
C. The reactions were terminated by separating free and bound radioactivity by 
rapid vacuum filtration using a Packard filtration manifold through GF/B pre-wetted 
glass fiber filters.  
Filters were rapidly washed two times with cold 10 mM NaH2PO4/10 mM Na2HPO4 
buffer, pH 7.4. Filters were transferred to vials for subsequent counting in a scintillation 
counter. Results are expressed as % of glutamate-induced response, the latter being 
32 
 
defined as 100%. Glutamate and amino acids were dissolved and diluted in water. 
Concentration–response curves were drawn on a logarithmic scale. Sigmoidal curves of 
best fit were calculated by nonlinear regression analysis using GraphPad software (San 
Diego, CA). The pIC50-value referred to the concentration of a compound producing half 
the maximum response. 
 
4.3.11 X-ray crystallographic data 
Single crystal X-ray diffraction data were collected at 150 K (8b,7c) or 298 K (8a) on a 
Bruker Smart diffractometer using Mo-Kα radiation (λ=0.71073 Å). Following solution 
by direct methods, the structures were refined against F
2
 with full-matrix least-squares 
using the program SHELXL-97
15
. All hydrogen atoms were added at calculated positions 
and refined by use of riding models with isotropic displacement parameters based on 
those of the parent atoms. Except for the minor components of the disordered atoms in 
(8b), anisotropic displacement parameters were employed throughout for the non-
hydrogen atoms. Crystallographic data (excluding structure factors) for the structures in 
this paper have been deposited with the Cambridge Crystallographic Data Centre as 
supplementary publication nos. CCDC 899273-899275. Copies of the data can be 
obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, 
UK, (fax: +44-(0)1223-336033 or e-mail: deposit@ccdc.cam.ac.uk). 
Crystal data: compound 8a, C24H25NO4; monoclinic, space group P21/c, a = 16.9344(19), 
b = 8.8127(10), c = 16.1275(18) Å, β = 117.393(2)°, V = 2137.0(4) Å
3
, Z = 4, Dc = 1.217 
g cm
-3
. 15529 reflections collected, 5280 independent (Rint = 0.034). Final R indices, R1 = 
0.0428 (for I > 2σ(I)), wR2 = 0.1223 (all reflections), S = 0.876. 
Compound 8b, C26H27NO4: monoclinic, space group P21/c, a = 16.035(4) , b = 9.114(2) , 
c = 16.769(4) Å, β = 117.079(4)°, V = 2182.0(9) Å
3
, Z = 4, Dc = 1.271 g cm
-3
. 24889 
reflections collected, 3750 independent (Rint = 0.056). Final R indices, R1 = 0.0930 (for I 
> 2σ(I)), wR2 = 0.2330 (all reflections), S = 1.157. The allyl group was modelled as being 
disordered over two sets of sites with occupancies refined to 0.773(13) and its 
complement. 
Compound 7c, C30H29NO4: triclinic, space group 1P , a = 6.0737(16) , b = 12.605(3) , c = 
17.285(5) Å, α = 70.961(4), β = 81.126(4), γ = 84.888(4)°, V = 1234.9(6) Å
3
, Z = 2, Dc = 
1.257 g cm
-3
. 14317 reflections collected, 6006 independent (Rint = 0.029). Final R 
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Legends for schemes and tables 
Scheme 1. Alkylation of α,β–unsaturated ester. 
Scheme 2. Synthesis of racemic 9 and 10. Reagents and conditions (a) KN(TMS)2, THF, -78 
o
C; RI or RBr; (b) 
10% aq. HCl, reflux. 
Scheme 3.  Synthesis of racemic 13 and 14. Reagents and conditions (a) (i) 1 M HCl, ether, RT, 16 h, (ii) Pd/C, 
H2, MeOH, RT, (b) 10% aq. HCl, reflux. 
Scheme 4. Synthesis of racemic 17 and 20. Reagents and conditions (a) HCHO, NaBH3CN, acetic acid, CH3CN 
(b) 10% aq. HCl, reflux, (c) Mg turnings, dry CH3OH, RT. 
Scheme 5. Synthesis of racemic 22. Reagents and conditions (a) (i) RCHO, THF, powdered molecular sieves (5 
Å), RT, (ii) NaBH3CN, acetic acid, MeOH; (b) 10% aq. HCl, reflux.  
 
Table 1 Isolated yields (%) of compounds 7 and 8. 
Table 2 Isolated yields (%) of compounds 9 and 10. 
Table 3 Isolated yields (%) of compounds 11, 12, 13 and 14. 
Table 4 Isolated yields (%) of compounds 21 and 22. 




Table 1 Isolated yields (%) of compounds 7 and 8. 
Table 2 Isolated yields (%) of compounds 9 and 10. 
Table 3 Isolated yields (%) of compounds 11, 12, 13 and 14. 
Table 4 Isolated yields (%) of compounds 21 and 22. 





Table 1  
Compounds 7 (%) 8 (%) 
a (R = Me) 48 6 
b (R = CH2CHCH2) 45 6 
c (R = Bn) 77 11 




Table 2  
Compounds 9 10 
a (R = Me) 86 80 
b (R = CH2CHCH2) 100 100 
c (R = Bn) 94 98 
d [R = (CH2)3Ph] 63 76 
  
  
Table 3  
Compounds 11 12 13 14 





b (R = Pr) 94 93 99 na
a
 
c (R = Bn) 66 70 86 85 
a
na : not attempted 
 
Table 4  
Compounds 21 22 
a (R = Ph) 80 98 
b (R = 2-pyridinyl) 80 100 
c (R = 3-pyridinyl) 58 98 
d [R = 3-(OH)C6H4] 81 92 
e [R = 4-(OH)C6H4] 69 95 
 
  
Table 5  
Compounds 
mGlu2-ago-AC,  
EC50  SD in M 
(Emax%) 
mGlu2-ago-GTP,  
EC50  SD in M 
(Emax%) 
mGlu2-antag-GTP,  
IC50  SD in M 
(Emax%) 





 45  10 (38%)
a
 60 (39%) 












 200 (67%) 
rac-17 3(51%) >100 >100 
rac-20 nd
b
 9.7  0.5 (34%) 47 (66%) 
rac-22b nd
b
 >100 75  11 (100%) 
rac-22c nd
b
 >100 >100 
a
Values from reference 7. 
b
nd: not determined. 
c
















































Legends for figures 1-10 
 
Figure 1. Conformationally restricted glutamate analogues. 
Figure 2. NOESY correlations for compound 7a.  
Figure 3. ORTEP diagram of the structure of compound 8a. Ellipsoids have been drawn at 
the 20% probability level. 
Figure 4. ORTEP diagram of the structure of compound 8b. Ellipsoids have been drawn at 
the 30% probability level. Minor components of disordered atoms were omitted for clarity. 
Figure 5. ORTEP diagram of the structure of compound 7c. Ellipsoids have been drawn at 
the 30% probability level. 
Figure 6. Suggested mechanism leading to the stereochemistry of compound 7. 
Figure 7. NOESY correlations for compound 18.  
Figure 8. Suggested mechanism leading to the stereochemistry of compound 18. 




Figure 10. Antagonist activity of 13b and antagonist activity of 22b at mGluR2. 
 
